Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ADC ST8176AA1 |
Synonyms | |
Therapy Description |
ADC ST8176AA1 is an antibody-drug conjugate (ADC) comprising Herceptin (trastuzumab), an ERBB2 (HER2) antibody, linked to ST7464AA1, which delivers the HDAC inhibitor to tumor cells expressing ERBB2 (HER2), potentially inhibiting Erbb2 signaling, and resulting in increased DNA damage and apoptosis, and reduced cell proliferation and tumor growth (PMID: 32039017). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ADC ST8176AA1 | Trastuzumab-HDACi ST8176AA1|ST8176AA1 ADC|ST8176AA1-ADC | HER2 (ERBB2) Antibody 72 HER2 (ERBB2) Antibody-Drug Conjugate 27 | ADC ST8176AA1 is an antibody-drug conjugate (ADC) comprising Herceptin (trastuzumab), an ERBB2 (HER2) antibody, linked to ST7464AA1, which delivers the HDAC inhibitor to tumor cells expressing ERBB2 (HER2), potentially inhibiting Erbb2 signaling, and resulting in increased DNA damage and apoptosis, and reduced cell proliferation and tumor growth (PMID: 32039017). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|